A phase II, open-label, multicentre, pharmacokinetic, pharmacodynamic and safety study of anagrelide hydrochloride in young (18-50 years) and elderly (greater than or equal to 65 years) patients with essential thrombocythaemia.

Trial Profile

A phase II, open-label, multicentre, pharmacokinetic, pharmacodynamic and safety study of anagrelide hydrochloride in young (18-50 years) and elderly (greater than or equal to 65 years) patients with essential thrombocythaemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2014

At a glance

  • Drugs Anagrelide (Primary)
  • Indications Embolism and thrombosis; Essential thrombocythaemia
  • Focus Pharmacokinetics
  • Sponsors Shire
  • Most Recent Events

    • 09 Jun 2009 Primary endpoints amended as reported by ClinicalTrials.gov.
    • 16 Jul 2008 Actual end date is now 1 Mar 2008 as reported by ClinicalTrials.gov.
    • 16 Jul 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top